Lot-to-lot consistency of live attenuated SA 14-14-2 Japanese encephalitis vaccine manufactured in a good manufacturing practice facility and non-inferiority with respect to an earlier product
- 1 October 2014
- Vol. 32 (46) , 6061-6066
Abstract
No abstract availableKeywords
Funding Information
- PATH (00945)
This publication has 16 references indexed in Scilit:
- Corrigendum to “Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants” [Vaccine 26 (2008) 2234–2241]Vaccine, 2014
- Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in SpainVaccine, 2013
- Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose scheduleHuman Vaccines, 2011
- Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of ageVaccine, 2009
- Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infantsVaccine, 2008
- Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case–control study in Nepalese children 5 years after immunizationVaccine, 2007
- Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004Vaccine, 2005
- Optimally weighted, fixed sequence and gatekeeper multiple testing proceduresJournal of Statistical Planning and Inference, 2001
- Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control studyThe Lancet, 1996
- Japanese encephalitis: a Chinese solution?The Lancet, 1996